- Juv on the Road
Packed with bold ideas, global collaboration, and a shared vision for a future built on preventative, personalised healthcare.
- Press Releases
M42 announces a strategic investment and partnership with Juvenescence, a leading biotech company focused on extending human healthspan. This collaboration aims to develop cutting-edge therapies and advance research in longevity and age-related diseases.
- In the News
Congratulations to the Relation team for securing this landmark partnership deal with GSK to advance therapeutics for fibrotic diseases and osteoarthritis. We're delighted and proud to be a founder investor in this great company.
- Press Releases
Extensive scientific research has long established the critical role of spermidine in activating autophagy, a vital cellular process that removes damaged cells and declines with age.
- In the News
Relation Therapeutics, a biotechnology company, today announced $35 million in new seed financing, bringing its total seed fundraise to $60 million.
- Press Releases
The next four patients will receive a higher dose of LyGenesis's cell therapy to grow functioning liver tissue in patients with end stage liver disease.
- Juv on the Road
Our co-founder Dr. Greg Bailey took to the stage in Riyadh at Hevolution Foundation hashtag#GHS2025 with fellow investment leaders.
- Juv on the Road
Reflecting on an inspiring & productive week at WHX Dubai - with the latest & best in healthcare innovation.
- Juv on the Road
This week, four members of the Juvenescence® team—Kersten Small, Jeff Madwed, Steve Felstead, and myself—had the privilege of visiting the Buck Institute for Research on Aging.
- Press Releases
Listen in to Prof Michael Levin & Prof David Kaplan discussing the Morphoceuticals vision and groundbreaking approach of mapping & manipulating the bioelectrome to induce regeneration.
- Juv on the Road
Bridging science and society to help achieve longer, healthier and more fulfilled lives for as many people as possible.
- Juv on the Road
I had the best time attending the 2024 Biomarkers of Aging Consortium Conference at Harvard Medical School !
- Juv on the Road
A fantastic first day at the The Longevity Forum in London, filled with valuable insights.
- In the News
New CEO set to Marshall longevity with a pipeline that delivers immediate therapeutic benefit, but always has an eye on a future preventative angle.
- In the News
The investment community is chasing a longer, healthier life like the rest of us.
- In the News
What makes longevity one of the greatest investment opportunities in human history?
- In the News
There’s a lot of great stuff happening, but it’s not one drug that’s going to keep you alive another 10 years in good health
- In the News
The leaders of the Buck Institute for Research on Aging want you to know that they’re not going to make you immortal.
- In the News
Longevity Technology reports on Juvenescence investment in the important work of MDI Therapeutics.
- In the News
Greg goes deep on Juvenescence, longevity biotech and his personal story.
- Press Releases
Juvenescence is a life sciences company developing therapies to modify aging and increase healthy human lifespan.
- In the News
Healthspan and longevity research has exploded in the past decade, and as scientists learn more about the biology of aging
- In the News
Everyone ages — it’s one of the indisputable facts of life. From the moment we are born, each one of us starts a linear process of growth and maturation
- Press Releases
A biopharmaceutical company focused on treating aging and age-related disease
- In the News
The human suffering is huge, and in the next 30 years, the number of over-65-year-olds is projected to double to 1.5 billion.
- In the News
Jim Mellon probably has a broader understanding of the progress being made confronting human aging than any other person alive.
- In the News
Dr. Bailey discusses the origins of Juvenescence as well as his belief that the nascent longevity industry is reaching an inflection point.
- Press Releases
Juvenescence is pleased to announce its latest biotech company Souvien Therapeutics (“Souvien”), creating innovative medicines to address neurodegenerative diseases by targeting the epigenetic underpinnings of neurodegeneration.
- Press Releases
Juvenescence is pleased to announce its latest equity investment in BYOMass Inc.
- Press Releases
The Buck Institute is one of the leading research centers in the world focused solely on research on aging and the elimination of age-related disease.